Page 4 - Bharat Biotech

Covid intranasal vaccine Phase III trials over, proven safe: Bharat Biotech

BBV154 was developed in partnership with Washington Univ St Louis, which had designed and developed recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy

Serum Institute explores new-age vaccine delivery systems for growth

The Pune-based company that manufactured the Covid-19 vaccine administered to most Indians is exploring more sophisticated delivery systems

Bharat Biotech expects regulator's nod for intranasal Covid vaccine in Aug

The Drug Controller General of India gave its nod to conduct clinical trials for BBIL's intranasal vaccine as booster dose

Bharat Biotech, ExcellGene consortium to develop variant-proof Covid vax

The consortium is developing or designing a new vaccine concept that confers highly cross-reactive protection against numerous SARS-CoV-2 variants of concern

Covaxin third shot gives long-term immunity: Nature Scientific study

Study shows booster jab is effective against several Sars-CoV-2 strains such as Alpha, Beta, Delta, Delta Plus and Omicron, and also increases memory B-cell response

Top Headlines: PSBs shareholding cap, growth of top firms, and more

The central government is seeking to remove the 10 per cent shareholding cap for individuals in public sector banks (PSBs). Read more in our top headlines

Bharat Biotech's Zika vaccine to enter Phase 2 clinical trials soon

In 2016, Big Pharma companies like Pfizer, Johnson & Johnson, and Merck were evaluating developing a Zika vaccine

Bharat Biotech's Covaxin induces wider immune response, say experts

However, experts say that Covaxin induces a wider immune response and thus antibody production against the spike protein may be less intense

Twitter accounts hyped US firm seeking trials for India-made Covid vaccine

Ocugen sought FDA approval for Covaxin in October, then a seeming coordinated social media effort lifted its stock.

Bharat Biotech's Covaxin is safe for children between 2 and 18 yrs: Lancet

Data from over 50 million doses reveals minimal side effects

Hundreds of millions of Covid vaccines in India to expire in September

Covaxin has a shelf life of 12 months, while Covishield, the vaccine that accounted for nearly 80% of India's vaccinations, has a shelf life of nine months

Paraguay cancels orders for one million doses of Covaxin, say sources

Media reports cite quality issues; sources say Bharat Biotech had stopped production and exports in April, any pending orders stand cancelled

Bharat Biotech's Covaxin phase-3 trial concluded successfully at AMU

The phase-3 trial for Covaxin was done in collaboration with the Indian Council of Medical Research (ICMR) and BBIL

Germany to recognize Bharat Biotech's COVAXIN for travel from June 1

WHO in November last year issued an emergency use listing (EUL) for COVAXIN, adding to a growing portfolio of vaccines validated for the prevention of COVID-19 caused by SARS-CoV-2

FDA lifts hold on clinical trials for phase 2,3 for Covaxin: Ocugem

"We're extremely pleased that we can proceed with our clinical trials for Covaxin our whole virus inactivated COVID-19 vaccine candidate," Dr Shankar Musunuri, CEO and Co-Founder, Ocugen Inc said

CEPI funds Bharat Biotech consortium project for variant-proof Covid-19 jab

CEPI has till date announced funding for nine such projects including the Bharat Biotech one

NTAGI meet this week to review vaccine data for 5-12 age group

A senior government official had told Business Standard last week that so far there was no scientific evidence to expand the vaccination programme to young children

Bharat Biotech must address vaccine issues raised by WHO, says MEA

Weeks after WHO suspended the supply of Covaxin through UN procurement agencies, the MEA suggested that Bharat Biotech addresses the issue immediately to avoid the cancellation

DCGI grants EUA to Corbevax for those aged 5-12, Covaxin for 6-12 age group

DCGI has granted emergency use authorisation for Biological E's Covid-19 vaccine Corbevax and Bharat Biotech's Covaxin

Bharat Biotech asked to provide more data on Covaxin for below 12-year-olds

This development comes after the Subject Expert Committee discussed recommendations for the restricted emergency of Covaxin in children aged between 2-12 years